Clinical Trial Update: A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes [Phase 2]

View source ↗

Summary

Phase II trial assessing subcutaneous exenatide (Bydureon) for glucose control in adults with Type I diabetes has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Bydureon (exenatide)
• EXENATIDE (EXENATIDE)

Snippet

Sponsor: Yale University | Conditions: Type I Diabetes | Phase 2 | Status: COMPLETED | Results posted: 2019-10-22